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INTRODUCTION 
Chest pain is a very common presentation at the Emergency room. 
The causes could range from benign, non life threatening ones to those 
that jeopardize life. Acute Coronary Syndrome is one common cause of chest 
pain belonging to the latter. Only 15-25% of patients with chest pain actually 
have ACS17. 
             Many a time, there is a doubtful situation in categorising patients with 
non ST elevation chest pain with regards to whether to follow them up or to 
evaluate them aggressively or discharge them. While it is too expensive to 
evaluate every such patient, discharging prematurely a patient with an 
impending Acute Coronary Syndrome is a serious professional misconduct. 
 Though there are many scores like TIMI, GRACE which helped in 
prognosticating an established acute coronary event, there was not an objective 
method available to risk stratify patients presenting with chest pain, to aid 
further decision namely early discharge or observation or intervention. 
 Then, in 2008, in Netherlands, Six et al put forward an objective method 
to risk stratify patients quickly, using minimum resources, called the HEART 
Score, utilising the History, ECG finding, Age, Risk factors, Troponin – all 
taken down on the spot at presentation. This score has been well validated by 
prospective studies. 
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 But the HEART score had some shortcomings such that the components 
were not given weightage in the score as per their importance. Hence to 
improve on the HEART score, the Erlanger HEARTS3 Score1, which uses 
likelihood ratio analysis to give appropriate weight to the individual elements 
of the HEART score as well as incorporating 3 additional variables viz, Sex, 
Serial 2ND hour ECG, and Serial 2ND hour Troponin during the initial  
emergency room evaluation was made. 
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AIM 
 The aim of my study is to risk stratify Non ST elevation chest pain 
patients in the Emergency Room using HEARTS3 Score, so that high risk 
patients can be evaluated and low risk patients can be discharged early, so that 
the resources need not be spent in evaluating all patients. 
OBJECTIVES 
The objective of my study is to 
 Determine the association between the HEARTS3 score and outcome in 
the form of Major Adverse Cardiac Event such as Myocardial 
Infarction, Cardiogenic shock, Cardiac arrest, all cause cardiac death 
upto 7 days in all patients presenting with non ST Elevation chest pain 
to the Emergency Room and 
 Validate the accuracy of the HEARTS3 Score in risk stratifying such 
patients. 
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REVIEW OF LITERATURE 
CHEST PAIN 
 According to CDC report of 20052, Chest pain accounts for about six 
million annual visits to Emergency Departments in the United States, making 
chest pain the second most common complaint. 
 The potential sources of chest pain could range anywhere from the skin 
upto the endocardium, including esophagus, stomach, abdominal viscera.  
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 Of the above mentioned causes, the life threatening causes which 
require immediate and prompt timely identification include: 
 Coronary Artery Disease as Acute Coronary Syndrome 
 Pulmonary embolism 
 Pneumothorax 
 Dissection of aorta 
 Pancreatitis 
 Hollow viscus rupture including esophageal tear. 
 The Myocardial ischemic pain due to Acute Coronary Syndrome is the 
commonest of the above mentioned dangerous etiologies of chest pain. 
 Pain originating from deeper visceral structures are poorly localised by 
the Central Nervous System due to common representations on the 
somatosensory cortex. 
NEUROLOGY OF CHEST PAIN.7,8 
 The pain originating from the viscera of the thorax namely the heart , 
lung (visceral pleura), oesophagus, great vessels are taken by the autonomic 
nerves. 
 With respect to the pain of myocardial origin, the pain is taken by 
sympathetic nerves that pass via the superior and inferior cardiac plexus, via 
cardiac nerves, pass through the sympathetic ganglia without synapsing to enter 
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into the spinal nerve via the white rami communicantes, enter the dorsal root 
ganglia of T1 to T4 spinal segments. 
 After Entering the spinal cord, the fibres ascend some two segments 
above and enter the posterior grey horn to terminate in the 2nd order neuron in 
Rexed lamina I and V. From there, the second order neurons cross over to the 
contralateral side and ascend in anterior spinothalamic tract. 
    
 The pain of visceral origin is poorly localised because, the viscera are 
poorly represented in the sensory homunculus in the post central gyrus. 
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 All organs receive their blood supply during systole. But the 
myocardium is perfused during diastole because, as the penetrating branches 
from the epicardial coronaries traverse the thickness of the myocardium, they 
get occluded by the myocardial contractive sheer during the systole. 
 The left ventricle owing to its greater myocardial muscle mass, the left 
ventricular blood vessels traverse a longer distance through the  myocardium 
than those of the right ventricle. This is depicted in the following diagram. 
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 Owing to the pattern of blood vessel arrangement, the subendocardial 
region is the most ischemia prone region. Though being end arteries, the 
penetrating branch ramifies to form a subendocardial arterial plexus. 
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 This image shows how the calibre of an intramural penetrating branch 
alters during systole and diastole. 
MYOCARDIAL ISCHEMIA 
 Myocardial ischemia occurs when there is a mismatch between 
myocardial oxygen demand and supply. 
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Acute myocardial ischemia results in acute chest pain. 
 The causes leading onto an acute myocardial ischemia can be classified 
under the following headings:16 
 CORONARY CAUSES 
 NON CORONARY, CARDIAC CAUSES 
 EXTRA CARDIAC CAUSES. 
CORONARY CAUSES OF ACUTE MYOCARDIAL ISCHEMIA: 
 Plaque rupture/ erosion 
 coronary vasospasm 
 spontaneous coronary dissection 
 microcirculatory defects 
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 coronary thrombosis (spontaneous) 
 embolus in coronary vasculature 
NON CORONARY, CARDIAC CAUSES OF ACUTE MYOCARDIAL 
ISCHEMIA: 
 Myocarditis 
 Takutsubo cardiomyopathy 
 Other cardiomyopathies 
 Cardiac trauma  
 Tachyarryhthmias 
 Cardiotoxic drugs 
NON CARDIAC CAUSES OF ACUTE MYOCARDIAL ISCHEMIA: 
 Pulmonary embolism 
 Sepsis 
 Adult Respiratory Distress Syndrome 
 End Stage Renal Disease 
 Of all the above mentioned causes, rupture of atherosclerotic plaque is 
the commonest cause for acute myocardial ischemia presenting to the 
Emergency Room with acute onset chest pain. 
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ATHEROSCLEROTIC CORONARY ARTERY DISEASE: 
              The hardening of arterial vessel wall and deposition of lipids on the 
intimal surface of the vessel is called atherosclerosis. The process of genesis of 
atherosclerotic plaque starts in childhood when the consumption of pro 
atherosclerotic diet like diet rich in cholesterol and saturated fats begins15. The 
initial deposition causes a yellowish raise on the intima and is called the 
FATTY STREAK. 
 
The arrows show the fatty streaks. 
 The traditional risk factors for atherosclerosis are the factors which 
actually promote inflammation, such as the following: 
 Physical injury or stress on the endothelium due to direct trauma 
or hypertension 
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 Turbulence of  blood flow, for example, where arteries branch 
 Reactive oxygen species (free radicals), e.g., from smoking or air 
pollutants 
 Hyperlipidemia (high blood concentrations of LDL or VLDL) 
 Chronically elevated blood glucose levels 
 Homocysteinemia, which results from an inherited metabolic defect that 
leads to very high levels of the homocysteine, a metabolite of 
methionine; high concentrations are toxic to the endothelium. 
    At the site of sheer stress and turbulence, lipoprotein molecules get 
adherent to the proteoglycan layer of the intimal endothelium and deposit in the 
intimal tunic. Owing to inflammation, the lipoprotein get modified by oxidation 
and glycation.  
            The modified lipoprotein further induces oxidative stress by inducing 
proinflammatory cytokine release which further aggravates local inflammation. 
 The expression of proinflammatory cytokines promotes the expression 
of cell adhesion molecules on the endothelium and recruits macrophages and 
other cells of inflammation.  
           The macrophages engulf the lipid molecules and such macrophage are 
called foam cells. Fibroblasts also home to the region of atherosclerosis and 
form a cap surrounding the lipid rich core. 
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           If the fibrous cap is thick, it means that the plaque is stable and if the 
fibrous cap is thin, then it may be prone for erosion or rupture and such plaques 
are called vulnerable plaques. 
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 This diagram shows a schematic representation of the development of 
atherosclerotic plaque: 
1. Low density Lipoproteins getting deposited in the tunica intima 
                              
       
2. Darker molecules show LDL molecules that are modified by oxidation 
or glycation 
                  
3. The green molecules are the proinflammatory cytokines the expression 
of which is induced by the oxidative stress created by the modified 
lipoproteins. These cytokines act as chemotactic factors for monocytes 
and induce the expression of cell adhesion molecules on the 
endothelium. This stage in the picture shows the margination of 
circulating monocytes aided by the pro inflammatory cytokine induced 
expression of cell adhesion molecules. 
 
 
4. Shows diapedesis of the monocyte into the tunica intima. 
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5. Activation of monocytes to macrophages, wherein they express 
scavenger receptors that aid in phagocytosis of the modified lipoprotein 
molecules by the macrophages. The lipid laden macrophages are called 
as FOAM CELLS. 
 
 
6. The foam cells elaborate a lot of reactive oxygen and reactive nitrogen 
species and many other chemotactic molecules, causing migration of 
the smooth muscle cells from the tunica media into tunica intima. 
 
 
7. The smooth muscle cells proliferate and cause deposition of 
Extracellular matrix, and hence the fatty streak is not converted to 
fibrofatty atherosclerotic plaque. 
 
 
 
8. The cells within the atherosclerotic plaque undergo necrosis and 
apoptosis and there occurs calcium deposition in the plaque. As the 
plaque grows in size, angiogenesis occurs to the plaque and the newly 
formed blood vessels are friable like that of the neovessels formed in a 
diabetic retina. 
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 The deposition of lipid starts early in life and the rate of progression or 
growth of the atherosclerotic plaque depends on the presence of the classical 
risk factors for atherosclerosis, which all aid in maintaining a proinflammatory 
state. 
 
THE GROWTH OF THE ATHEROSCLEROTIC PLAQUE: 
 
 The above graphs depict the pattern of atherosclerotic plaque growth. 
The age old concept as depicted by the graph on the left was that the 
atheromatous plaque once formed, the rate of its growth is uniformly 
progressive with the age. 
 The recent concept is that, the growth of atherosclerotic plaque is not 
uniform. It shows a serpentine or a stepladder type of growth rather than a 
smoothly progressive curve. That is the as the plaque grows, its growth may 
fall into a quiescence phase owing to factors like plaque rupture or plaque 
hemorrhage, which may or may not be clinically significant. 
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CORONARY ATHEROSCLEROSIS: 
 Atherosclerotic plaques even though if present, they can be 
asymptomatic. There came the concept of SIGNIFICANT Coronary 
atherosclerotic disease, which is defines based on Coronary Angiogram 
features. 
Significant coronary atherosclerosis is defined as the29, 
 presence of plaque occluding 50% or more in Left Main Stem artery 
 plaque occluding 70% or more of the lumen of other major coronary 
vessel 
 plaque occluding 30-70% of the lumen with a Fractional Flow 
Reserve (FFR) of  ≤ 0.8. 
 Fractional flow reserve is the ratio of the intraluminal pressure distal to 
the stenosis to the intraluminal pressure proximal to the stenosis. 
 Angiographic guide wire with pressure sensor is used to measure 
pressure proximal and distal to the stenosis. 
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STABLE AND VULNERABLE PLAQUES: 
 Post mortem studies in patients who had fatal myocardial infarction 
have revealed that their atherosclerotic plaques had a common feature. There 
evolved the concept of stable and vulnerable atherosclerotic plaques. 
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 Stable plaques are those plaques that are covered by a thick fibrous cap 
on their luminal side. Vulnerable plaques are those plaques that are covered by 
a thin fibrous cap overlying a dense lipid core that is necrotic. 
 The thin fibrous cap is prone for rupture thereby exposing the 
prothrombotic lipid core and hence called as vulnerable plaque19. 
 
 Various methods have been introduced and studied to study the 
characteristics of a plaque such as Intravascular ultrasonography, Optical 
Coherence Tomography, CT Coronary Angiography and MRI. 
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CLINICAL MANIFESTATIONS OF SIGNIFICANT CORONARY 
ATHEROSCLEROTIC DISEASE: 
 
STABLE ANGINA 
 Patients with significant coronary atherosclerosis can walk around 
asymptomatically also. 
 Some patients with a stable plaque, may be asymptomatic at rest, as the 
reduced blood flow occurring despite the plaque may be sufficient to meet the 
oxygen demands of the myocardium at rest. 
 But in situations where the myocardial oxygen demand increases such as 
during exercise, the fixed plaque leading to a decreased coronary blood flow 
would not be sufficient in meeting the increased oxygen demand. So there 
occurs myocardial ischemia that leads onto the patient experiencing anginal 
pain. 
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 But once the myocardial oxygen demand decreases as when the patient 
stops exercising, the adequacy of blood supply now to the myocardium 
matches the oxygen demand and the angina gets relieved. 
 This is a DEMAND LED ISCHEMIA due to a fixed STABLE 
plaque and this syndrome is called STABLE ANGINA. It is a clinical 
syndrome and the ECG remains normal and there is no Troponinaemia. 
UNSTABLE CORONARY SYNDROMES 
 An unstable or vulnerable plaque may undergo plaque rupture, which is 
the rupture of the fibrous cap, or may undergo erosion of the overlying 
endothelium, thus exposing the underlying necrotic lipd core which is 
prothrombotic, thus setting off the coagulation cascade leading to the formation 
of platelet plug quickly followed by a thrombus at the site of catastrophe. 
 A rapidly forming thrombus increases and occludes the lumen 
progressively, thereby causing an abrupt decrease in blood SUPPLY to the 
myocardium, leading to ischemia of the myocardium which presents as pain 
occurring at rest or that which started during exertion but not relieved by rest. 
 This is SUPPLY LED ISCHEMIA, due to a ruptured or eroded 
unstable plaque. 
THIS IS ACUTE CORONARY SYNDROME 
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 The image above is a low power histopathological section of coronary 
arterial thrombus that had occurred following plaque erosion. 
 The image below shows a Scanning Electron Microscopy image of 
superficial plaque erosion, exposing the subendothelium. The arrow marks 
show the leucocytes that have started to adhere to the denuded surface. 
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 The image shown below is Optical Coherence Tomography image of 
plaque rupture. The arrow heads mark the endothelial discontinuity.30 
 
The asterisk represents the lipid rich core of the plaque. 
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 The image below is Optical Coherence Tomography image of a 
thrombus that had formed over the ulcer created by plaque rupture. 
 
Arrows show the thrombus. 
 Plaque rupture is responsible for 75% of the Acute Coronary Syndromes 
and is more common in men, whereas Plaque erosion is commoner in ACS 
occurring in women less than 50 years of age. But Plaque rupture predominates 
the cause leading to ACS in older women. 
 The plaque characteristics of a vulnerable plaque that could lead onto an 
ACS have been studied. The following are the morphological characteristics of 
dangerous plaques:18,19 
 Lipid burden >70% 
 Thin fibrous cap 
 
29
 Causing a luminal area of 4 mm sq. or lesser 
 Expansive remodelling which stretches and thins out the fibrous cap 
and minimizing luminal obstruction, leading to a misleadingly mild 
stenosis on coronary angiography. 
 Plaque hemorrhage 
 Neovascularisation  
 Spotty pattern of calcification 
 Adventitial inflammation. 
 An acute increase in inflammatory burden could precipitate a plaque 
rupture, as inflammation leads to overexpression of enzymes that degrade the 
plaques extracellular matrix. This is the reason behind vaccinating people with 
high risk coronary artery disease risk with Pneumococcal and Influenza 
vaccinations as an episode of these infections could result in an acute increase 
in the inflammatory burden leading onto plaque rupture, thereby precipitating 
an acute coronary syndrome. 
 Other factors leading to plaque rupture are 
 Stress induced by intraluminal pressure 
 Tachycardia (cyclical stretching and compression) 
 Coronary vasomotor tone. 
       Many physiologic parameters namely systolic blood pressure, heart rate, 
blood viscosity, plasminogen activator inhibitor-1 (PAI-1) level,  plasma  
cortisol levels, and plasma epinephrine levels exhibit circadian and seasonal 
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variations and increase at times of stress. These factors act in concert to 
heighten the propensity for plaque disruption and coronary thrombosis, with 
the result that STEMI clusters in the early morning hours, especially in the 
winter and after natural disasters21-23 
 Not all plaque ruptures or erosions will lead onto the formation of a 
thrombus that progresses to occlude the lumen completely. What determined 
the thrombus size can be classified into the factors in the blood and factors in 
the lipid plaque per se, which are grouped as 
 Fluid phase determinants 
 Solid state determinants. 
     The following schematic represents the two state model of 
atherothrombosis. The vulnerable plaque has a thin fibrous cap covering a large 
lipid core that contains abundant tissue factor–bearing macrophages. When the 
fibrous cap ruptures, pro coagulant proteins in the fluid phase of blood gain 
contact with tissue factor–bearing macrophages and microparticles derived 
from apoptotic cells present in the solid state of the plaque. These events 
trigger thrombus formation on the ruptured plaque. The consequences depend 
on the amount of tissue factor and apoptosis in the plaque’s core and on the 
levels of fibrinogen and Plasminogen Activator Inhibitor-1 in the blood. This 
interaction of the fluid phase with the solid state will determine whether a 
given plaque disruption provokes a partial or transient coronary artery 
occlusion (that can be clinically silent or less commonly cause an episode of 
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unstable angina) or a devastating persistent and an occlusive thrombus that can 
lead to an acute myocardial infarction. Inflammation regulates the 
thrombotic/fibrinolytic balance in both the solid state and the fluid phase, 
because PAI-1 and fibrinogen both are acute-phase reactants and because the 
inflammatory mediator CD40 ligand (CD154) induces tissue factor expression. 
 
 The fate of rupture of vulnerable plaque is an Acute Coronary 
Syndrome, which depending upon the fluid phase and solid state determinants 
has the size of thrombus causing an episode of Unstable Angina or going on to 
lead onto myocardial infarction namely Non ST Elevation or ST Elevation 
myocardial infarction. 
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ACUTE CORONARY SYNDROME 
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 An Acute Coronary Syndrome occurs when the coronary blood flow is 
reduced suddenly and severely due to atherothrombus plaque rupture/The 
myocardium supplied by the occluded artery will immediately become 
ischemic. If blood flow is not restored rapidly, the ischemic area will undergo 
infarction(necrosis) which leads to irreversible cell death. The infarction will 
commence in the most ischemic area and from there it will gradually expand. 
 If the artery is completely occluded, all ischemic myocardium will be 
dead in 2 to 12 hours. The size of the ischemic or necrotic area correlates 
strongly with the risk of heart failure, malignant ventricular arrhythmias and 
other complications. 
 An Acute Coronary syndrome occurs when an atherosclerotic plaque 
disrupts, which results in activation of platelets and coagulation factors 
ultimately forming a thrombus, which occludes the artery. 
 The occlusion can be partial or complete depending upon the size of the 
thrombus and the plaque itself. 
 Acute Coronary Syndromes can be divided into ST Elevation ACS and 
Non ST Elevation ACS. ST Elevation ACS is the ST Elevation Myocardial 
Infarction called as STEMI where there is a transmural myocardial infarction 
leading onto the development of ST segment elevation on the ECG along with 
cardiac biomarker positivity, the diagnosis of which is not difficult owing to 
the typical ECG patterns defined in the 3RD   and 4TH UNIVERSAL 
DEFINITIONS OF MYOCARDIAL INFARCTION6. 
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 The Non ST Elevation ACS include the Non ST Elevation Myocardial 
Infarction called as NSTEMI and Unstable Angina. 
 In NSTEMI, there is infarction leading to cardiac biomarker positivity 
but the infarct is not transmural and hence there is no ST segment elevation. 
But ECG shows other features of ischemia. On the other hand, in Unstable 
Angina, there is no infarction and hence cardiac biomarker negativity. ECG 
shows features of ischemia but again, not ST elevation. 
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 As for STEMI, there is no clear definition framed for NSTE-ACS and if 
left untreated, around 50% of the patients may proceed on to have full blown 
STEMI. 
 Hence timely recognition of NSTE-ACS is crucial. The significance of 
time is depicted in the image below:12,13 
 
 Hence when intervened on time, the progressive thrombus formation can 
be aborted, Infarction can be prevented and myocardium can be salvaged. 
 The representation above depicts the consequences of reperfusion at 
various times after coronary occlusion. In the above image, the mid portion of 
the left anterior descending coronary artery is occluded and a large zone of 
ischemic myocardium develops, called the “area at risk.” If Reperfusion occurs 
in less than 20 minutes, it does not result in permanent loss of tissue, but for a 
transient period of myocardial contractile dysfunction called “stunning”. If 
 
36
reperfusion occurs later, it results in hemorrhagic necrosis with contraction 
bands. Permanent occlusion results in necrosis of myocardium.   
 
 The importance of the above graph is that it depicts the importance of 
timely identification of Acute Coronary Syndrome. Though the myocardial 
function declines rapidly following ischemia (as depicted by the blue curve), 
The myocardium remains viable for a longer period (as depicted by the red 
curve) which can be salvaged if aggressively managed. 
 The following image shows the schematic representation of the three 
major epicardial coronaries and the areas subtended by their supply which are 
prone to ischemia or infarction if they are occluded.14 
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 Electrocardiogram is a very useful basic diagnostic tool in the diagnosis 
of coronary artery disease, as the leads overlying specific regions of the heart 
pick up the ischemic changes occurring there giving us clue about the culprit 
artery . 
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The ischemic T wave inversions: 
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CARDIAC TROPONINS:  
 Cardiac Troponins are the preferred biomarker to detect myocardial 
injury. They are present within the myocyte, enclosed by the intact 
sarcolemma. In conditions of myocyte injury, the ensuing sarcolemmal 
disruption leads to these intracellular molecules shed into the circulation. 
 The presence of Cardiac Troponins in the general circulation, called 
Troponinaemia, signifies myocardiocyte disruption or injury, whatever be the 
cause24-25.  
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 Myocyte necrosis due to infarction leads to cardiac specific troponins 
being found in the serum at a magnitude proportional to the degree of myocyte 
necrosis. 
 Troponins are basically molecules that are present in the contractile 
machinery of  striated muscle. There are three subunits namely 
 Troponin C 
 Troponin T  
 Troponin I 
 Troponin C binds calcium. Troponin T binds to Tropomyosin and 
Troponin I binds to actin and inhibits actin – myosin interaction. 
 Cardiac and skeletal muscle Troponin T and I are encoded by different 
genes and hence cardiac Troponins are different isoforms from that of skeletal 
muscle Troponins. Hence specific antibodies specific for cardiac troponins are 
produced and are made use of in the detection of serum level of these 
biomarkers. 
 Most of the Cardiac Troponin T is incorporated into the contractile 
complex and about 6-8% of it is dissolved in the cytosol, whereas only 2-3% of 
the Troponin I is dissolved in the cytosol. Following myocyte injury, initially, 
the cytosolic pool of cardiac Troponins are released into the circulation and 
subsequently the components in the myofilaments are released into the 
circulation.26-27 
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 In patients with Myocardial Infarction, cardiac Troponin T and I begin 
to rise by about 3 hours after the onset of chest pain. Because of continuous 
release from a degenerating contractile apparatus in necrotic myocytes, 
elevations in cardiac Troponin I may persist for 7 to 10 days after MI and 
elevations in cardiac Troponin T may persist for up to 10 to 14 days. 
 Variations in the cutoff for abnormal levels of cardiac Troponin I in 
clinically available immunoassays result from the different specificities of the 
antibodies used for detecting free and complexed cardiac Troponin I. For both 
the cardiac Troponins, the definition of an abnormally increased level is a value 
exceeding that of 99% of a reference control group. Assays that have a level of 
imprecision (coefficient of variation) of less than 10% at the specific 99th 
percentile cutoff are optimal for clinical practice. 
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 The above image shows the troponin and myoglobin in the myocyte and 
their release into the circulation following myocyte injury. 
 The timeline of serum concentrations of various cardiac biomarkers 
following myocardial infarction:28 
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 The graph above depicts the level of rise in serum concentration of 
highly sensitive cardiac Troponin T above the 99th percentile in various 
conditions. The same graph holds good for cardiac Troponin T also. 
 With clear definitions not made for diagnosis, to identify the NSTE-
ACS during triage at the Emergency Room, Six et al from Netherlands framed 
the HEART Score comprising of components from the History of the nature of 
chest pain, the ECG features of ischemia, Age of the patient, Risk factors, 
Troponin levels, giving each component an equal weightage in the score, with 
the score ranging from 0 to 10 was framed. 
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endpoint of MACE occurring in 6 weeks. The study concluded that the 
HEART score provides the clinician with a quick and reliable predictor of 
outcome, without computer-required calculating and that, Low HEART scores 
(0-3), exclude short-term MACE with >98% certainty and so in those patients 
that one might consider reserved policies. Also the study concluded that in 
patients with high HEART scores (7-10) the high risk of MACE may indicate 
more aggressive policies.3,4  
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 A Prospective validation study of the HEART Score was conducted in 
Sundaram Medical Foundation, Chennai, India, published in the International 
Journal of Emergency Medicine in 2015, studied 87 patients with chest pain, 
with HEART Score following them for the endpoint of occurrence of MACE at 
30 days. It found that high HEARTS Score (score of 7 to 10), showed 93% 
sensitivity and 98% specificity in predicting the occurrence of MACE at 30 
days.5 
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 The shortcomings of the HEART score were that all the components 
were weighed equally. While Troponin positivity and ECG changes are more 
definitive in establishing NSTE-ACS, the other components of the score are not 
objective enough in doing so. Hence by using regression analysis, each 
component was given a different score. 
 Also the HEART score, is recorded at the time when the patient presents 
to the Emergency Room. As the ECG changes of ischemia and Troponin levels 
are dynamic, the score was modified as HEARTS3 SCORE where the Sex of 
the patient, Serial ECG at 2nd hour and Serial Troponin levels at 2nd hour are 
taken into account and the new score of HEARTS3 SCORE was framed. The 
HEARTS3 Score was developed by Fesmire et al, at University of Tennessee 
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College of Medicine, Chattanooga, Tennessee, USA, in 2012. They conducted 
a retrospective analysis in prospectively acquired data in patients with NSTE 
chest pain, comparing HEART and HEARTS3 Scores. There was a significant 
difference in area under the ROC for both (0.958 vs 0.825 for HEARTS3 and 
HEART Scores) for the occurrence of ACS at 30 days. The study concluded 
that the HEARTS3 Score reliably risk stratified chest pain patients for 30 day 
ACS, and that PROSPECTIVE Studies needed to be performed to determine 
implementation of this score can guide decision regarding treatment and 
disposition in the emergency room.1. 
HEARTS3 SCORE 
HISTORY 
HEARTS3  
SCORE 
                  PROBABLE NON CARDIAC CHEST PAIN 0
                  POSSIBLE ISCHEMIC CHEST PAIN 1
                  PROBABLE ISCHEMIC CHEST PAIN 4
ECG(BASELINE) 
                  ABSENCE OF ISCHEMIC ECG CHANGES 0
                  OLD INFARCT/BBB/HYPERTROPHY 1
                  ISCHAEMIC ST DEPRESSION OR T            
INVERSION 3
AGE IN YEARS 
                  <45  0
                  >45 1
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NO.OF RISK FACTORS 
      0 TO 2 0
      3 TO 6 1
TROPONIN T(BASELINE) 
        <THE CUT OFF 0
        1-3X THE CUT OFF 2
        >3X THE CUT OFF 5
SEX 
       FEMALE 0
       MALE 1
SERIAL ECG 
       NO CHANGE 0
       NO DIAGNOSTIC ISCHAEMIC CHANGE 2
       DIAGNOSTIC ISCHAEMIC CHANGE 5
SERIAL TROPONIN T AT 2HOURS 
       <+0.1ng/ml FROM BASELINE 0
       +0.1-0.3ng/ml FROM BASELINE 2
       >+0.3ng/ml FROM BASELINE 5
The HEARTS3 Score ranges from 0 to 25. 
 
           As time is very crucial, an unstable angina if left untreated may progress 
on to NSTEMI and STEMI leaving an infarct in the myocardial tissue. The 
ultimate aim is to salvage the myocardium from infarction. 
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MATERIAL AND METHODOLOGY 
STUDY DESIGN: 
                                Prospective observational study 
STUDY PERIOD: 
                                 6 months 
STUDY AREA: 
                                Government Kilpauk Medical College Hospital. 
STUDY POPULATION: 
 Adults, 18 years and older presenting with chief complaints of chest 
pain to the Emergency Room in Government Kilpauk Medical College 
Hospital, Chennai, during the study period January 2018 to June 2018, were 
included in the study. 
SAMPLE SIZE 
         The sample size is calculated using Openepi application, with 
Confidence level of 95%, proportion with outcome (MACE) of 30% and 
accuracy (absolute) of 20%, and  the sample size is found to be 100. 
INCLUSION CRITERIA 
 Adults, 18 years and older of either gender, presenting with chief 
complaints of chest pain to the emergency room. 
EXCLUSION CRITERIA 
        All patients presenting with STEMI are excluded from the study. 
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METHODOLOGY 
 We were informed about the arrival of the patients meeting the inclusion 
criteria, presenting at the Emergency Room of Kilpauk Medical College 
Hospital by the attending duty physician at the emergency room at any time 
24x7.With the informed written consent from the patient, the patient will be 
enrolled in the study. The HEARTS3 score was framed for the patient  with the 
History, ECG, Age, history of Risk factors, Troponin, Sex, Serial ECG and 
Serial troponin at 2 hours. 
 The patient was followed up and was observed for any Major Adverse 
Cardiac Event (MACE), such as Myocardial Infarction, Cardiogenic shock, 
Cardiac arrest, all cause cardiac death, upto 7 days of initial presentation. 
CASE DEFINITION 
HISTORY 
               The patient’s typicality of chest pain will be assessed from the 
history. As guided by the 2014 AHA ACC guideline for NSTEMI ACS, 
NSTEMI ACS11 most commonly presents as a pressure-type chest pain that 
typically occurs at rest or minimal exertion lasting for 10 minutes or more. The 
patients presenting with all the characteristics mentioned above are classified to 
have probable ischemic chest pain. 
 The patients presenting with some of the above mentioned 
characteristics of chest pain are classified to have possible ischemic chest pain. 
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Features not characteristic of ischemic chest pain include18: 
 Pleuritic pain( sharp or knifelike pain provoked by respiration or 
cough); 
 Primary or sole location of discomfort in the middle or lower abdomen; 
 Pain localized by the tip of 1 finger, particularly at the left ventricular 
apex or costochondral junction; 
 Pain reproduced with movement or palpation of the chest wall or arms; 
 Brief episodes of pain lasting a few seconds or less; 
 Pain that is of maximal intensity at onset; and  
 Pain that radiates to lower extremities. 
 The patients presenting with any one of the above mentioned 
presentations are classified to have probable Non cardiac chest pain. 
ECG 
           An ECG is obtained on arrival to the emergency room and is looked for 
the presence of ST segment elevation in continuous leads and they are excluded 
from the study. ECG with straightline or downsloaping ST depression 0.05mV 
or more or symmetrical T inversion 0.2mV or more in continuous leads are 
grouped as probable ischemia and are given 3 points.  
The presence of chamber hypertrophy, old infarct or bundle branch block on 
ECG can confound changes of ACS and are grouped to have possible ischemia 
and are given 1 point. 
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 The ECG is repeated after 2 hours of presentation and is looked for the 
appearance of ischemic change and points are given as per the table given 
further. 
AGE 
           Points are given as per the patient’s age 
RISK FACTORS 
            The number of risk factors present among Diabetes mellitus, 
hypertension, hyperlipidemia, smoking in the past 1 month, family history of 
Coronary Artery Disease will be enquired and the patient’s BMI will be 
measured and will be categorized for obesity if the BMI is 30 kg/sq.meter or 
more. Points will be given as per the number of risk factors present 
TROPONIN 
            The patient’s blood is drawn and Troponin T levels are measured on 
arrival and is taken as the baseline Troponin T. The 99th percentile of the upper 
reference level as determined by the lab is taken as the cut-off and is given 
points according to whether the Baseline Troponin T is below the cut off or 1 
to 3 times the cut off or more than 3 times the cut off.  
SEX 
            Point given depends on the gender. 
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STATISTICAL ANALYSIS 
 
 The data was collected in the master chart obtained in the Microsoft 
excel format. 
 The collected data were analysed with IBM.SPSS statistics software 
23.0 Version. To describe about the data descriptive statistics frequency 
analysis, percentage analysis were used for categorical variables and the mean 
& S.D were used for continuous variables. To find the efficacy of 
theHEARTS3 Score, Sensitivity, Specificity, PPV and NPV and diagnostic 
accuracy with Receiver Operating Curve (ROC)   was used. In the above 
statistical tool the probability value .05 is considered as significant level.  
 
 
 
 
 
 
 
 
                  
 Of 
accounting
table and p
 
 
 
  
Valid 
 The numb
the 100 
 to 51% m
ie chart be
51%
MALE
FEMA
Total 
er of subj
subjects st
ales and 
low. 
Gender
FE
 
LE 
58
RESUL
ects enroll
udied, 51
49% fema
 distrib
MALE MA
GEND
TS 
ed in my s
 were ma
les, which
49%
ution
LE
ER 
Frequen
tudy were 
les and 4
 is shown
cy 
51 
49 
100 
100. 
9 were f
 in the fre
 
Perc
emales, 
quency 
ent 
51.0
49.0
100.0
  Of 
from  21 t
were 20, 5
were 5, re
population
and the hi
study subj
diagram as
                 
  
Valid 
 
0
5
10
15
20
25
30
2
the 100 su
o 30 years
1 to 60 y
spectively 
, and the l
ghest age 
ects is 50
 below. Th
                
21 - 
31 - 
41 - 
51 - 
61 - 
Abo
Tota
1 - 30 yrs 31
10
bjects en
 were 10, 
ears were 
making 10
owest age
is 76 year
.80 years, 
e Y axis s
                A
30 yrs 
40 yrs 
50 yrs 
60 yrs 
70 yrs 
ve 70 yrs
l 
 - 40 yrs 41 -
20
Age
59
rolled in t
between 3
19, 61 to 
%, 20%, 
 of the sub
s , the ran
which is s
hows the n
GE 
F
50 yrs 51 - 6
20
 distrib
he study, 
1 to 40 ye
70 years w
20%, 19%
ject inclu
ge being 5
hown in t
umber of 
requency
1
2
2
1
2
10
0 yrs 61 - 70
19
2
ution
number o
ars were 2
ere 26 an
, 26% and
ded in the 
3 and the
he frequen
subjects. 
Per
0
0
0
9
6
5
0
 yrs Above 7
yrs
6
5
f subjects 
0, 41 to 5
d above 7
 5%  of th
study is 2
 mean age
cy table a
cent 
10.0 
20.0 
20.0 
19.0 
26.0 
5.0 
100.0 
0 
of age 
0 years 
0 years 
e study 
3 years 
 of the 
nd bar 
 
 
60
N Minimum Maximum Mean 
Std. 
Deviation 
AGE 100 23 76 50.80 14.311 
Valid N 
(listwise) 
         
 
           Of the 100 subjects, 44 had HEARTS3 Score from 0-5, accounting for 
44%, 7 had score from 6-10, accounting for 7%, 7 had score from 11-15, 
accounting for 7%,  34 had score from 16-20, accounting for 34% and 8 had 
score from 21-25, accounting for 8%. 
HEARTS3 SCORE 
  Frequency Percent
 0 - 5 44 44.0
6 - 10 7 7.0
11-15 7 7.0
16-20 34 34.0
21-25 8 8.0
Total 100 100.0
 
  The
shown bel
HEARTS
 0- 5
6-10
11 -
16 -
21 -
Total 
 
0
5
10
15
20
25
30
35
40
45
 gender d
ow: 
HEAR
3 SCORE
 Coun
% wi
GEN
 Coun
% wi
GEN
 15 Coun
% wi
GEN
 20 Coun
% wi
GEN
 25 Coun
% wi
GEN
Coun
% wi
GEN
0 - 5
44
istribution
TS3 SCO
 
t 
thin 
DER 
t 
thin 
DER 
t 
thin 
DER 
t 
thin 
DER 
t 
thin 
DER 
t 
thin 
DER 
6 - 10
7
Heart
61
 of vario
RE GEN
M
11 - 15
7
 3 Score
us HEAR
DER Cro
GEN
ALE 
19
37.3%
4
7.8%
4
7.8%
19
37.3%
5
9.8%
51
100.0%
16 - 20
34
 %
TS3 Scor
ss tabulati
DER 
FEMA
1
21 - 25
8
 
e subgrou
on 
LE 
25 
51% 
3 
6.1% 
3 
6.1% 
15 
30.6% 
3 
6.1% 
49 
00.0% 
ps are 
Total 
44
44.0%
7
7.0%
7
7.0%
34
34.0%
8
8.0%
100
100.0%
                  
with HEA
were fema
(5/8) were
                 
are studied
the graph: 
The Y axis
0%
20%
40%
60%
80%
100%
             Fr
RTS3 Sco
les. Wher
 males and
          The
 and the m
 shows the
F
Gen
0 - 5
om, the ge
re 16-20,
eas, of the
 37.5% (3/
 age distri
ean age o
 age in ye
EMALE
der wi
6 - 10
62
nder distr
55.8% (1
 subjects 
8) were fe
bution for
f the subje
ars. 
th Hear
11 - 15 1
ibution it i
9/34) were
with HEA
males. 
 various H
cts in each
MALE
t3 Scor
6 - 20 21 -
s found th
 males an
RTS3 Sco
EARTS3
 score sub
e 
25
 
at of the s
d 44.1% 
re 21-25,
 Score sub
group is sh
ubjects 
(15/34) 
 62.5% 
groups 
own in 
  
Score N
0 - 5 
6 - 10 
11 - 15 
16 - 20 
21 - 25 
Total 
 
 Of 
Cardiac Ev
Wall moti
of the subj
56% and i
0
10
20
30
40
50
60
70
O. MeanAge 
44 45
7 44
7 61
34 56
8 60
100 51
the 100 s
ent in the
on abnorm
ects did n
s depicted 
45
0 - 5
M
 Standar
Deviatio
 14.88
 15.20
 7.12
 10.62
 12.81
 14.31
ubjects, 4
 form of m
ality on th
ot have an
as follows
44
6 - 10
ean Ag
63
d 
n 
Std. 
Error 
0 2.243
7 5.748
8 2.694
7 1.822
7 4.532
1 1.431
4 of them
yocardia
e Echocar
y Major A
: 
6
11 
e with 
95%
Confide
Interval 
Mean
Lower 
Bound 
U
B
40.18 4
30.22 5
54.55 6
52.03 5
49.28 7
47.96 5
 had the
l infarction
diogram, 
dverse Ca
1
- 15 1
Heart3
 
nce 
for 
 
Min
pper 
ound 
9.23
8.35
7.74
9.44
0.72
3.64
 outcome
 as eviden
accounting
rdiac Even
56
6 - 20
 Score
imum 
age 
M
23 
26 
49 
36 
40 
23 
, Major A
ced by R
 for 44% 
t, accoun
60
21 - 25
 
aximum 
age 
76
70
68
73
76
76
dverse 
egional 
and 56 
ting for 
  
 
 
V
 
alid Ye
No
To
 
56%
64
MAC
Fr
s 
 
tal 
MAC
Yes
E 
equency
44
56
100
E
No
Percent
44.0
56.0
100.0
44%
 
 
65
 Sensitivity and specificity were found out for each HEARTS3 Score as 
cut off and are tabulated below: 
Coordinates of the Curve 
Test Result Variable(s): HEARTS3 
SCORE 
Positive if 
Greater Than 
or Equal Toa Sensitivity 
1-
Specificit
y 
-1.00 1.000 1.000
.50 1.000 .982
1.50 1.000 .875
2.50 1.000 .750
3.50 1.000 .589
4.50 1.000 .375
6.00 1.000 .214
7.50 1.000 .179
8.50 1.000 .143
9.50 1.000 .125
11.00 1.000 .089
13.00 1.000 .036
14.50 .955 .036
16.00 .955 0.000
17.50 .750 0.000
18.50 .432 0.000
19.50 .318 0.000
20.50 .182 0.000
21.50 .091 0.000
22.50 .045 0.000
23.50 .023 0.000
25.00 0.000 0.000
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 The ROC Curve is plotted with the above tabulated true positive and 
false positive values as coordinates for each HEARTS3 Score as cut off and the 
ROC Curve was obtained as follows: 
 
         The Area Under the ROC Curve is 0.998 and standard error is 0.002, 
determined with confidence interval of 99.5% (p value =0.005), which is 
shown below. 
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Area Under the Curve 
Test Result Variable(s): HEARTS3 SCORE 
Area Std. Errora 
Asymptotic 
Sig.b 
Confidence 
Interval 
Lower 
Bound
Upper 
Bound 
.998 .002 .0005 .995 1.000 
a. Under the nonparametric assumption 
b. Null hypothesis: true area =0.5 
 P - Value ** Highly Significant at P ≤ .01 
  Based on the collected data of this study, on taking HEARTS3 Score 
cut off of 16 and below as low score and HEARTS3 score more than 16 as high 
score, Specificity was found to be 100% and sensitivity of 95.45%. Of the 100 
subjects studied, 58 of them had low score and 42 had high score. 
 All the 42 subjects with high score had MACE (outcome) on observing 
upto 7 days. Of the 58 subjects with low score, 2 had MACE and 56 did not 
have MACE on observing upto 7 days, which is shown in the confusion matrix 
as follows: 
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Cut off 16 
Sensitivity 95.45 
Specificity 100.00 
PPV 100.00 
NPV 96.55 
Accuracy 97.73 
  
   For the above cut off limit of HEARTS3 score, Positive Predictive 
Value for MACE is 100% and Negative Predictive value is 96.55% and the 
accuracy is 97.73%. 
 
 
 
HEARTS3 SCORE * MACE Cross tabulation 
Count 
  
MACE 
Total Yes No 
HEARTS3 
SCORE 
> 16 42 0 42
<= 16 2 56 58
Total 44 56 100
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DISCUSSION 
 Acute Coronary Syndrome, comprising of Unstable Angina, and Non 
ST segment Elevation Myocardial Infarction known as NSTEMI and ST 
segment Elevation Myocardial Infarction known as STEMI is the commonest 
etiology of acute chest pain that is life threatening. As their name goes, these 
conditions namely Unstable Angina and NSTEMI are unstable in that when not 
recognised on time and managed appropriately, the rupture of the unstable 
atherosclerotic plaque which had led on to these unstable acute coronary 
syndromes may progress with the platelet plug and the ensuing thrombus going 
on to occlude the entire lumen of the artery leading to transmural infarction that 
becomes ST segment Elevation Myocardial infarction. 
 The ischemic or the infarcted piece of myocardium may lead on to 
injury currents which can lead onto dangerous tachyarrhythmias like 
Ventricular Tachycardia which may deteriorate to Ventricular Fibrillation, 
which is fatal when not managed on a war footing emergency basis. The 
incidence of these malignant arrhythmias are highest during the first 24 hours 
of the onset of myocardial ischemia. 
 The ischemic or infarcted myocardium can lead on to myocardial 
dysfunction manifesting as cardiac failure the severity of which depends on the 
size of myocardium hypoperfused. The dysfunction can be as severe to cause 
cardiogenic shock and / or acute pulmonary edema. 
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 So fearing these complications and managing every patient who presents 
with acute chest pain to the emergency room with sophisticated cardiac 
monitoring is expensive. While certain patients present with chest pain that 
looks seemingly of coronary etiology, the absence of ischemic changes on the 
ECG at the outset at presentation may baffle us. It is a routine customary to 
record Serial ECGs for such patients. While what may be possibly ischemic 
chest pain by what the patient says alone and the first ECG alone may not be 
helpful in deciding whether to observe  or admit or discharge the patient, when 
ECG changes are absent or not contributory to an underlying ischemic process. 
Taking into account his risk factors for coronary artery disease still it may be 
difficult to decide on such patients in the grey zone.  
 In many resource poor setting, for the benefit of doubt, as to not to 
MISS an ongoing coronary event, patients are admitted and they are given 
antiplatelet and antithrombotic agents, based on just the presence of chest pain 
and ECG features not typical of ischemia. A good fraction of such patients who 
were subjected to coronary angiograms thereafter did not demonstrate 
significant coronary arterial disease. There have been observational studies 
done for the same9. 
 This adds to the patient care cost and anxiety.  
 So to consolidate all the characteristics to a cumulative score that can 
detect a coronary event as the etiology of the chest pain reliably was needed 
from which HEART Score was developed, and validated3,4,5. 
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 To improvise the shortcomings of the HEART Score, HEARTS3 score 
was formed. The HEARTS3 Score required validation based on prospective 
studies1 and this study is a prospective study to validate its efficiency. 
 Based on the Area Under ROC curve of 0.998, it is shown that 
HEARTS3 score is an efficient test and with having a cut off of 16 and below 
as low score and more than 16 as high score, the HEARTS3 scoring system 
efficiently and reliably segregates patients presenting with chest pain at the 
emergency room as those would probably land up in MACE in 7 days and 
those would probably not. 
 Hence HEARTS3 Score more than 16 suggests that the etiology of chest 
pain is Acute Coronary Syndrome in patients presenting with chest pain at the 
ER. Hence such patients can be admitted and those with lower scores can be 
observed and planned for early discharge. 
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LIMITATIONS OF THIS STUDY AND SCOPE FOR 
FUTURE STUDIES: 
 This study has observed for MACE occurring upto 7 days from the 
presentation of chest pain. Though this is the time period wherein there is 
maximum risk of MACE occurrence following ACS, 30 day MACE incidence 
should be studied to compare efficiency of HEARTS3 Score with the HEART 
score as previous studies done with HEART Score have observed for 30 day 
MACE occurrence.  
 The score takes 2nd hour serial ECG and 2nd hour Troponin,  thus 
making the score available only by the end of 2nd hour. The score can be 
modified to HEARTS Score( rather than previous HEART) omitting 2nd hour 
serial values and ECG to be obtained at the time spot of presentation and 
validated for a Cutoff value for ACS. And if the cutoff is not met with the 
HEARTS Score, ie., low HEARTS score, patient may be proceeded to have the 
full HEARTS3 Score at the end of 2 hours of presentation, before the patient be 
considered for early discharge. 
 With point of care Echocardiographic imaging being available and 
physicians are being made to train in rapid echo screening, presence of 
Regional Wall Motion Abnormality can be incorporated into the score to 
improvise the score’s sensitivity. 
 Highly Sensitive Troponin T levels may be incorporated into the score, 
which can be detected earlier than the Troponin, which may improve the 
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sensitivity of the HEARTS score at the time when patient presents to the 
Emergency Room. 
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CONCLUSION 
 Chest pain is a common presentation at the Emergency Room. Rapid 
identification of ACS is a crucial component of the triage. 
                        
 HEARTS3 Score is an efficient score in triaging acute chest pain 
patients at the Emergency Room. 
 Patients with score more than 16 are more likely to have acute 
coronary syndrome and may be managed in Coronary Care Unit and those 
with lower scores may be planned for early discharge, hence avoiding the 
generalised use of  cardiac monitoring for all patients with chest pain, hence 
decreasing cost and patient anxiety. 
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SUMMARY 
 There was no objective score to triage chest pain patients in the 
emergency room prior to 2008. Then there came the HEART Score by Six, 
Backus et al. The shortcomings of the HEART Score were overcome by the 
improvised form of the score called the HEARTS3 Score. 
 The HEARTS3 Score has been shown to be more accurate than the 
HEART Score in effectively picking up ACS. But the efficacy of the 
HEARTS3 Scoe has not been validated by prospective studies. 
 My study is a prospective observational study to validate the accuracy of 
the HEARTS3 Score. The HEARTS3 Score of more than 16 is 100% specific 
for ACS and 95.45% sensitive. 
 Hence HEARTS3 score can be used in the emergency room triage 
protocol for chest pain with scores more than 16 being managed in coronary 
care units and scores of 16 and less may be planned for early discharge or 
observation. 
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ANNEXURES: 
                                                   PROFORMA 
Name            :                                                 Age :                              Sex:                                 
Address        :                                                  IP / OP No: 
Date:                                              Time of presentation at the ER: 
 
Contact No   :  
Height 
Weight 
BMI 
Chest pain:  Character of pain: 
                      Onset of pain during: 
                      Pain since: 
                      Any other detail of the chest pain 
ECG finding at presentation 
 
 
RISK FACTORS: 
                       Diabetes mellitus 
                       Hypertension 
                       Dyslipidemia 
                       Family history of CAD 
                       Smoking in the last 1 month 
                       Obesity 
TROPONIN T level at presentation 
Serial ECG finding at 2 hours after arrival 
Serial Troponin T level at 2 hours after arrival 
HEARTS3 SCORE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
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DA
YS
1 60 MALE 4 1 1 1 2 1 5 5 20 YES
2 48 MALE 4 3 1 1 2 1 2 5 19 YES
3 68 MALE 1 1 1 1 2 1 5 5 17 YES
4 45 MALE 4 3 1 1 2 1 5 2 19 YES
5 56 MALE 4 1 1 1 2 1 2 5 17 YES
6 64 MALE 4 3 1 1 0 1 5 5 20 YES
7 73 MALE 4 1 1 0 2 1 5 5 19 YES
8 48 MALE 1 3 1 1 5 1 5 2 19 YES
9 59 MALE 4 3 1 1 2 1 5 2 19 YES
10 70 MALE 4 3 1 0 5 1 2 5 21 YES
11 58 MALE 4 3 1 1 5 1 5 2 22 YES
12 62 MALE 1 1 1 1 2 1 5 2 14 YES
13 60 MALE 4 3 1 1 0 1 5 5 20 YES
14 45 MALE 1 5 1 1 2 1 5 2 18 YES
15 66 MALE 4 3 1 1 2 1 5 5 22 YES
16 44 MALE 4 1 0 1 3 1 2 5 17 YES
17 43 MALE 4 3 0 1 5 1 5 5 24 YES
18 40 MALE 0 3 0 1 2 1 5 5 17 YES
19 44 MALE 4 1 0 1 0 1 5 5 17 YES
20 41 MALE 1 1 0 0 5 1 5 5 18 YES
21 42 MALE 4 0 0 1 2 1 5 5 18 YES
22 38 MALE 1 3 0 1 5 1 2 5 18 YES
23 42 MALE 4 0 0 0 2 1 5 5 17 YES
24 36 MALE 1 3 0 1 5 1 2 5 18 YES
25 40 MALE 4 3 0 0 5 1 5 5 23 YES
26 62 FEMALE 1 3 1 1 5 0 5 2 18 YES
27 69 FEMALE 4 3 1 1 2 0 2 5 18 YES
28 65 FEMALE 4 3 1 0 5 0 2 5 20 YES
29 70 FEMALE 1 3 1 1 2 0 5 5 18 YES
30 76 FEMALE 4 3 1 1 2 0 5 5 21 YES
31 58 FEMALE 4 1 1 0 5 0 5 2 18 YES
32 59 FEMALE 1 3 1 1 5 0 5 5 21 YES
33 56 FEMALE 4 3 1 1 5 0 2 2 18 YES
34 60 FEMALE 4 0 1 0 2 0 5 5 17 YES
35 62 FEMALE 1 3 1 1 5 0 5 2 18 YES
36 68 FEMALE 1 3 1 1 5 0 5 5 21 YES
37 66 FEMALE 4 1 1 1 0 0 5 5 17 YES
38 55 FEMALE 4 3 1 0 2 0 2 2 14 YES
39 59 FEMALE 0 3 1 1 5 0 5 5 20 YES
40 62 FEMALE 1 3 1 1 5 0 2 5 18 YES
41 68 FEMALE 1 3 1 1 2 0 5 5 18 YES
42 62 FEMALE 4 3 1 1 2 0 5 2 18 YES
43 64 FEMALE 4 1 1 1 0 0 5 5 17 YES
44 59 FEMALE 0 3 1 1 5 0 5 5 20 YES
45 23 MALE 0 1 0 0 0 1 0 0 2 NO
46 36 MALE 4 0 0 0 0 1 2 0 7 NO
47 29 MALE 0 1 0 1 0 1 2 0 5 NO
48 32 MALE 1 1 0 0 0 1 2 2 7 NO
49 26 MALE 0 0 0 1 0 1 2 0 4 NO
50 40 MALE 0 1 0 0 0 1 2 0 4 NO
51 42 MALE 0 0 0 0 0 1 0 0 1 NO
52 40 MALE 1 1 0 1 0 1 0 0 4 NO
53 32 MALE 0 0 0 0 0 1 0 0 1 NO
54 30 MALE 1 1 0 0 0 1 0 0 3 NO
55 45 MALE 1 1 1 0 0 1 0 0 4 NO
56 58 MALE 0 0 1 1 0 1 2 0 5 NO
57 49 MALE 4 1 1 1 2 1 2 0 12 NO
58 48 MALE 0 0 1 0 0 1 0 0 2 NO
59 50 MALE 1 0 1 1 0 1 0 0 4 NO
60 50 MALE 0 1 1 0 0 1 0 0 3 NO
61 70 MALE 1 1 1 1 2 1 2 0 9 NO
62 54 MALE 0 0 1 0 0 1 2 0 4 NO
63 68 MALE 4 1 1 1 2 1 2 0 12 NO
64 72 MALE 0 0 1 1 0 1 2 0 5 NO
65 52 MALE 4 1 1 1 0 1 2 0 10 NO
66 76 MALE 1 0 1 0 0 1 0 0 3 NO
67 62 MALE 0 1 1 0 0 1 2 0 5 NO
68 71 MALE 0 1 1 1 0 1 0 0 4 NO
69 64 MALE 1 0 1 0 0 1 2 0 5 NO
70 66 MALE 4 1 1 1 2 1 2 0 12 NO
71 40 FEMALE 1 0 0 0 0 0 2 0 3 NO
72 36 FEMALE 1 0 0 0 0 0 2 0 3 NO
73 31 FEMALE 0 1 0 0 0 0 0 0 1 NO
74 38 FEMALE 0 1 0 1 0 0 0 0 2 NO
75 26 FEMALE 4 1 0 1 0 0 2 0 8 NO
76 30 FEMALE 0 0 0 0 0 0 0 0 0 NO
77 28 FEMALE 4 0 0 0 0 0 0 0 4 NO
78 26 FEMALE 1 1 0 2 0 0 2 0 5 NO
79 24 FEMALE 1 1 0 2 0 0 0 0 3 NO
80 25 FEMALE 4 0 0 0 0 0 0 0 4 NO
81 36 FEMALE 0 1 0 1 0 0 2 0 4 NO
82 40 FEMALE 4 3 0 1 0 0 2 0 10 NO
83 34 FEMALE 1 0 0 0 0 0 2 0 3 NO
84 43 FEMALE 0 1 0 1 0 0 0 0 2 NO
85 35 FEMALE 4 0 0 0 0 0 0 0 4 NO
86 40 FEMALE 1 1 0 1 0 0 2 0 5 NO
87 44 FEMALE 1 1 0 1 0 0 2 0 5 NO
88 42 FEMALE 0 1 0 1 0 0 0 0 2 NO
89 40 FEMALE 1 0 0 0 0 0 0 0 1 NO
90 38 FEMALE 4 0 0 0 0 0 0 0 4 NO
91 48 FEMALE 0 0 1 0 0 0 2 0 3 NO
92 54 FEMALE 1 3 1 1 0 0 2 0 8 NO
93 67 FEMALE 0 0 1 0 0 0 0 0 1 NO
94 60 FEMALE 4 3 1 1 2 0 2 2 15 NO
95 66 FEMALE 1 0 1 0 0 0 0 0 2 NO
96 55 FEMALE 1 0 1 0 0 0 0 0 2 NO
97 53 FEMALE 1 1 1 0 0 0 0 0 3 NO
98 66 FEMALE 0 0 1 0 0 0 0 0 1 NO
99 68 FEMALE 4 3 1 1 2 0 2 2 15 NO
100 70 FEMALE 4 0 1 0 0 0 0 0 5 NO
சுயஒப்ᾗதல் பᾊவம்  
ஆய்ᾫ ெசய்யப்பᾌம் தைலப்ᾗ: “அவசரப் பிrவில் ெநஞ்சு வலியின் 
அபாய அளைவ HEARTS3 மதிப்ெபண்ணின் வழியாகக் 
கண்டறியும் துல்லியத்ைதப் பrேசாதிக் கும் ஓர் ஆய்வு.” 
 
இடம்:           ெபாᾐ மᾞத்ᾐவத்ᾐவ த் ᾐைற  
                       அரசு  கீழ்பாக்கம் மᾞத்ᾐவக் கல்ᾥாி மᾞத்ᾐவமைன 
                       ெசன்ைன 
 
பங்குெபᾠபவாின்  ெபயர் : 
பங்குெபᾠபவாின்  வயᾐ :    பங்குெபᾠபவாின்  எண் : ேமேல 
குறிப்பிட்ᾌள்ள மᾞத்ᾐவ ஆய்வின் விவரங்கள் எனக்கு விளக்கப்பட்டன.  நான் 
இவ்வாய்வில் தன்னிச்ைசயாக பங்ேகற்கிேறன்.  எந்த காரணத்தினாேலா எந்த 
சட்டசிக்கᾤக்கும் உட்படாமல் நான் இவ்வாய்வில் இᾞந்ᾐ 
விலகிக்ெகாள்ளல்லாம் என்ᾠம் அறிந்ᾐ ெகாண்ேடன். 
இந்த ஆய்ᾫ சம்பந்தமாகேவா,  இைத சார்ந்ᾐ ேமᾤம் ஆய்ᾫ 
ேமற்ெகாள்ᾦம்ேபாᾐம் இந்த ஆய்வில்பங்கு ெபᾠம் மᾞத்ᾐவர் என்ᾔைடய 
மᾞத்ᾐவ அறிக்ைககைள பார்ப்பதற்கு என் அᾔமதி ேதைவயில்ைல என 
அறிந்ᾐ ெகாள்கிேறன்.  இந்த ஆய்வின் ᾚலம் கிைடக்கும் தகவைலேயா, 
ᾙᾊைவேயா பயன்பᾌத்திக்ெகாள்ள மᾠக்க மாட்ேடன். 
இந்த ஆய்வில் பங்கு ெகாள்ள ஒப்ᾗக்ெகாள்கிேறன்.   இந்த ஆய்ைவ 
ேமற்ெகாள்ᾦம் மᾞத்ᾐவ அணிக்கு உண்ைமᾜடன் இᾞப்ேபன் என்ᾠம் 
உᾠதியளிக்கிேறன். 
 
பங்ேகற்பவாின்   ைகெயாப்பம்                             ஆய்வாளாின்   ைகெயாப்பம் 
இடம் : 
ேததி : 
                                   
                                     PATIENT CONSENT FORM 
Study detail:     
“STUDY TO VALIDATE THE ACCURACY OF HEARTS3 SCORE IN 
RISK STRATIFYING CHEST PAIN IN THE EMERGENCY ROOM” 
Study centre  : KILPAUK  MEDICAL COLLEGE, CHENNAI 
Patients Name : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict   the use of 
any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well-being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   place   date 
Signature of investigator :    
Study investigator’s Name :                       place   date      
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DA
YS
1 60 MALE 4 1 1 1 2 1 5 5 20 YES
2 48 MALE 4 3 1 1 2 1 2 5 19 YES
3 68 MALE 1 1 1 1 2 1 5 5 17 YES
4 45 MALE 4 3 1 1 2 1 5 2 19 YES
5 56 MALE 4 1 1 1 2 1 2 5 17 YES
6 64 MALE 4 3 1 1 0 1 5 5 20 YES
7 73 MALE 4 1 1 0 2 1 5 5 19 YES
8 48 MALE 1 3 1 1 5 1 5 2 19 YES
9 59 MALE 4 3 1 1 2 1 5 2 19 YES
10 70 MALE 4 3 1 0 5 1 2 5 21 YES
11 58 MALE 4 3 1 1 5 1 5 2 22 YES
12 62 MALE 1 1 1 1 2 1 5 2 14 YES
13 60 MALE 4 3 1 1 0 1 5 5 20 YES
14 45 MALE 1 5 1 1 2 1 5 2 18 YES
15 66 MALE 4 3 1 1 2 1 5 5 22 YES
16 44 MALE 4 1 0 1 3 1 2 5 17 YES
17 43 MALE 4 3 0 1 5 1 5 5 24 YES
18 40 MALE 0 3 0 1 2 1 5 5 17 YES
19 44 MALE 4 1 0 1 0 1 5 5 17 YES
20 41 MALE 1 1 0 0 5 1 5 5 18 YES
21 42 MALE 4 0 0 1 2 1 5 5 18 YES
22 38 MALE 1 3 0 1 5 1 2 5 18 YES
23 42 MALE 4 0 0 0 2 1 5 5 17 YES
24 36 MALE 1 3 0 1 5 1 2 5 18 YES
25 40 MALE 4 3 0 0 5 1 5 5 23 YES
26 62 FEMALE 1 3 1 1 5 0 5 2 18 YES
27 69 FEMALE 4 3 1 1 2 0 2 5 18 YES
28 65 FEMALE 4 3 1 0 5 0 2 5 20 YES
29 70 FEMALE 1 3 1 1 2 0 5 5 18 YES
30 76 FEMALE 4 3 1 1 2 0 5 5 21 YES
31 58 FEMALE 4 1 1 0 5 0 5 2 18 YES
32 59 FEMALE 1 3 1 1 5 0 5 5 21 YES
33 56 FEMALE 4 3 1 1 5 0 2 2 18 YES
34 60 FEMALE 4 0 1 0 2 0 5 5 17 YES
35 62 FEMALE 1 3 1 1 5 0 5 2 18 YES
36 68 FEMALE 1 3 1 1 5 0 5 5 21 YES
37 66 FEMALE 4 1 1 1 0 0 5 5 17 YES
38 55 FEMALE 4 3 1 0 2 0 2 2 14 YES
39 59 FEMALE 0 3 1 1 5 0 5 5 20 YES
40 62 FEMALE 1 3 1 1 5 0 2 5 18 YES
41 68 FEMALE 1 3 1 1 2 0 5 5 18 YES
42 62 FEMALE 4 3 1 1 2 0 5 2 18 YES
43 64 FEMALE 4 1 1 1 0 0 5 5 17 YES
44 59 FEMALE 0 3 1 1 5 0 5 5 20 YES
45 23 MALE 0 1 0 0 0 1 0 0 2 NO
46 36 MALE 4 0 0 0 0 1 2 0 7 NO
47 29 MALE 0 1 0 1 0 1 2 0 5 NO
48 32 MALE 1 1 0 0 0 1 2 2 7 NO
49 26 MALE 0 0 0 1 0 1 2 0 4 NO
50 40 MALE 0 1 0 0 0 1 2 0 4 NO
51 42 MALE 0 0 0 0 0 1 0 0 1 NO
52 40 MALE 1 1 0 1 0 1 0 0 4 NO
53 32 MALE 0 0 0 0 0 1 0 0 1 NO
54 30 MALE 1 1 0 0 0 1 0 0 3 NO
55 45 MALE 1 1 1 0 0 1 0 0 4 NO
56 58 MALE 0 0 1 1 0 1 2 0 5 NO
57 49 MALE 4 1 1 1 2 1 2 0 12 NO
58 48 MALE 0 0 1 0 0 1 0 0 2 NO
59 50 MALE 1 0 1 1 0 1 0 0 4 NO
60 50 MALE 0 1 1 0 0 1 0 0 3 NO
61 70 MALE 1 1 1 1 2 1 2 0 9 NO
62 54 MALE 0 0 1 0 0 1 2 0 4 NO
63 68 MALE 4 1 1 1 2 1 2 0 12 NO
64 72 MALE 0 0 1 1 0 1 2 0 5 NO
65 52 MALE 4 1 1 1 0 1 2 0 10 NO
66 76 MALE 1 0 1 0 0 1 0 0 3 NO
67 62 MALE 0 1 1 0 0 1 2 0 5 NO
68 71 MALE 0 1 1 1 0 1 0 0 4 NO
69 64 MALE 1 0 1 0 0 1 2 0 5 NO
70 66 MALE 4 1 1 1 2 1 2 0 12 NO
71 40 FEMALE 1 0 0 0 0 0 2 0 3 NO
72 36 FEMALE 1 0 0 0 0 0 2 0 3 NO
73 31 FEMALE 0 1 0 0 0 0 0 0 1 NO
74 38 FEMALE 0 1 0 1 0 0 0 0 2 NO
75 26 FEMALE 4 1 0 1 0 0 2 0 8 NO
76 30 FEMALE 0 0 0 0 0 0 0 0 0 NO
77 28 FEMALE 4 0 0 0 0 0 0 0 4 NO
78 26 FEMALE 1 1 0 2 0 0 2 0 5 NO
79 24 FEMALE 1 1 0 2 0 0 0 0 3 NO
80 25 FEMALE 4 0 0 0 0 0 0 0 4 NO
81 36 FEMALE 0 1 0 1 0 0 2 0 4 NO
82 40 FEMALE 4 3 0 1 0 0 2 0 10 NO
83 34 FEMALE 1 0 0 0 0 0 2 0 3 NO
84 43 FEMALE 0 1 0 1 0 0 0 0 2 NO
85 35 FEMALE 4 0 0 0 0 0 0 0 4 NO
86 40 FEMALE 1 1 0 1 0 0 2 0 5 NO
87 44 FEMALE 1 1 0 1 0 0 2 0 5 NO
88 42 FEMALE 0 1 0 1 0 0 0 0 2 NO
89 40 FEMALE 1 0 0 0 0 0 0 0 1 NO
90 38 FEMALE 4 0 0 0 0 0 0 0 4 NO
91 48 FEMALE 0 0 1 0 0 0 2 0 3 NO
92 54 FEMALE 1 3 1 1 0 0 2 0 8 NO
93 67 FEMALE 0 0 1 0 0 0 0 0 1 NO
94 60 FEMALE 4 3 1 1 2 0 2 2 15 NO
95 66 FEMALE 1 0 1 0 0 0 0 0 2 NO
96 55 FEMALE 1 0 1 0 0 0 0 0 2 NO
97 53 FEMALE 1 1 1 0 0 0 0 0 3 NO
98 66 FEMALE 0 0 1 0 0 0 0 0 1 NO
99 68 FEMALE 4 3 1 1 2 0 2 2 15 NO
100 70 FEMALE 4 0 1 0 0 0 0 0 5 NO
